Novo Nordisk CEO Mike Doustdar looked over the shoulder of the U.S. President, Donald Trump, in November when a new price agreement on obesity medicine was signed with the American administration. (Archive photo). Photo: Jonathan Ernst/Reuters
Novo: 1.5M using weight-loss drug copies
In the U.S., approximately 1.5 million patients use a generic version of weight loss drugs, including Novo Nordisk’s Wegovy, according to the Danish company’s top executive, Mike Doustdar. These generic producers, known as “compounders,” have successfully met patient demand by offering lower...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?